Market Research Report
Rotavirus Infections - Pipeline Review, H1 2020
|Published by||Global Markets Direct||Product code||251575|
|Published||Content info||55 Pages
Delivery time: 1-2 business days
|Rotavirus Infections - Pipeline Review, H1 2020|
|Published: April 30, 2020||Content info: 55 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rotavirus Infections - Pipeline Review, H1 2020, provides an overview of the Rotavirus Infections (Infectious Disease) pipeline landscape.
Rotavirus is a virus that infects the bowels. Rotavirus is the most common cause of severe diarrhea among infants and children. Transmission of rotavirus most often occurs through fecal-oral contact. Usually, this occurs from poor hand washing or from ingestion of contaminated food or water. The virus may also be transmitted through the respiratory tract or by other body fluids, but these routes are less common. The virus may live on inanimate surfaces, such as doorknobs, toys, and hard surfaces. Symptoms may include severe diarrhea, vomiting, fever, and dehydration.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rotavirus Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Rotavirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Rotavirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rotavirus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical, Discovery and Unknown stages comprises 1, 3, 1, 1 and 1 molecules, respectively.
Rotavirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.